Task order: colorectal cancer prevention by a novel EPA analogue TP-252 and naproxen in FAP and lynch syndrome models
Ended Awarded Last action
- Contract number
- 75N91019F00132
- Awardee
-
University Of Alabama At Birmingham UEI YND4PLMC9AN7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,498,586
Award facts
- Opportunity
- Contract value 100% obligated
- $1,498,585.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Birmingham, AL 35294, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | -$7,825 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $554,176 | |
| Other Administrative Action | $0 | |
| Original award | $952,235 |
About this award
This federal contract award was made by the National Cancer Institute, a civilian agency, to the University of Alabama at Birmingham (UAB) under the PREVENT Preclinical Drug Development Program (PREVENT). The $1,498,585.64 task order is for the research and development of a novel EPA analogue TP-252 and naproxen for colorectal cancer prevention in familial adenomatous polyposis (FAP) and Lynch syndrome models. The contract has no set-aside designation.
UAB has performed numerous federal contracts and grants for the National Institutes of Health and other agencies, leveraging its expertise in cancer research, neuroscience, and biomedical engineering. Under this award, UAB is collaborating with the University of Connecticut Health Center as a subcontractor to conduct the colorectal cancer prevention study. The PREVENT program supports early-stage drug development for cancer prevention, which aligns with the National Cancer Institute's mission to advance cancer research and improve public health outcomes.
Quick answers
Who was awarded contract 75N91019F00132?
75N91019F00132 was awarded to University Of Alabama At Birmingham by National Cancer Institute (National Institutes of Health) on September 15, 2019.
How much is contract 75N91019F00132 worth?
The government has obligated $1,498,586 on 75N91019F00132.
Is contract 75N91019F00132 an order under another contract?
Yes. 75N91019F00132 is a delivery order under 75N91019D00019, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91019F00132 competed?
The extent of competition for 75N91019F00132 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award